Page last updated: 2024-10-25

clofazimine and Pneumonia

clofazimine has been researched along with Pneumonia in 7 studies

Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.

Pneumonia: Infection of the lung often accompanied by inflammation.

Research Excerpts

ExcerptRelevanceReference
" However, clinical implications may be restricted owing to poor solubility and low bioavailability rendering a suboptimal drug concentration in the target organ."5.91Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation. ( Jadhav, K; Jhilta, A; Ray, E; Sharma, N; Shukla, R; Singh, AK; Singh, R; Verma, RK, 2023)
" The following areas were emphasized at the conference: multiresistant gram-positive bacteremias in patients with serious underlying infections, azithromycin's effectiveness against acute community-acquired pneumonia, results of clarithromycin plus ethambutol in HIV-infected patients with MAC bacteremia, duodenal ulcers associated with Helicobacter pylori infections, and use of roxithromycin against AIDS-related cryptosporidium diarrhea."3.69Macrolides, azalides, and streptogrammins. ( Prescott, LM, 1996)
" However, clinical implications may be restricted owing to poor solubility and low bioavailability rendering a suboptimal drug concentration in the target organ."1.91Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation. ( Jadhav, K; Jhilta, A; Ray, E; Sharma, N; Shukla, R; Singh, AK; Singh, R; Verma, RK, 2023)
"Clofazimine (CFZ) is used to treat pulmonary non-tuberculous mycobacterial (NTM) infection; however, its pharmacokinetics remain unexplored in patients with pulmonary NTM, and the relationship between CFZ serum concentration and adverse effects has not been investigated."1.72Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection. ( Fujiwara, K; Furuuchi, K; Hanada, K; Hiramatsu, M; Kurashima, A; Morimoto, K; Ohta, K; Shiraishi, Y; Uesugi, F; Watanabe, F; Yoshiyama, T, 2022)
"Clofazimine is an antimicrobial agent that has activity in vitro against mycobacteria."1.46Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection. ( Daley, CL; Levin, A; Martiniano, SL; Nick, JA; Sagel, SD; Wagner, BD, 2017)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's3 (42.86)24.3611
2020's3 (42.86)2.80

Authors

AuthorsStudies
Watanabe, F1
Furuuchi, K1
Hanada, K1
Fujiwara, K1
Uesugi, F1
Hiramatsu, M1
Yoshiyama, T1
Shiraishi, Y1
Kurashima, A1
Ohta, K1
Morimoto, K1
Sriram, D1
Wahi, R1
Maggioncalda, EC1
Panthi, CM1
Lamichhane, G1
Jadhav, K1
Jhilta, A1
Singh, R1
Ray, E1
Sharma, N1
Shukla, R1
Singh, AK1
Verma, RK1
Martiniano, SL1
Wagner, BD1
Levin, A1
Nick, JA1
Sagel, SD1
Daley, CL1
Ruth, MM1
van Ingen, J1
Jarand, J1
Davis, JP1
Cowie, RL1
Field, SK1
Fisher, DA1
Prescott, LM1

Other Studies

7 other studies available for clofazimine and Pneumonia

ArticleYear
Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection.
    Antimicrobial agents and chemotherapy, 2022, 08-16, Volume: 66, Issue:8

    Topics: Clofazimine; Drug-Related Side Effects and Adverse Reactions; Humans; Lung Diseases; Nontuberculous

2022
Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice.
    Tuberculosis (Edinburgh, Scotland), 2022, Volume: 137

    Topics: Anti-Bacterial Agents; Clofazimine; Humans; Lung Diseases; Microbial Sensitivity Tests; Mycobacteriu

2022
Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation.
    Biomaterials advances, 2023, Volume: 154

    Topics: Animals; Clofazimine; Inflammation; Mice; Pneumonia; Respiratory Aerosols and Droplets; Tuberculosis

2023
Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.
    Chest, 2017, Volume: 152, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Child; Clofazimine; Dose-Respo

2017
New insights in the treatment of nontuberculous mycobacterial pulmonary disease.
    Future microbiology, 2017, Volume: 12

    Topics: Anti-Bacterial Agents; Clofazimine; Humans; Mycobacterium Infections, Nontuberculous; Nontuberculous

2017
Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin.
    Chest, 2016, Volume: 149, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clofazimine; Drug Therapy, Combination; Etham

2016
Macrolides, azalides, and streptogrammins.
    Journal of the International Association of Physicians in AIDS Care, 1996, Volume: 2, Issue:4

    Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; B

1996